Member Info for BasilAlderman

15k down the drain with MGC. I won't be investing in any more companies that Stephen Parker is involved in. Period. I'm going to watch what he does at Sareum like a hawk from now on.

Some very informative posts on this board over the last 48 hours. Thank you. The fact that United Therapeutics’ market value gained over $300 million on the back of Prevail's investment was, to say the least, very exciting for all HEMO share holders. We obviously have the right partner on board with Prevail. They certainly have an impressive track record of helping small companies get in to clinical trials and therefore creating value. This all bodes well for the coming days, weeks and months ahead as we head in to the clinic. I will review my investment strategy in HEMO when we hit 20p. This is a long term hold for me.

What the RNS should state is MGC Pharmaceuticals wipes out existing shareholders. Have these directors no shame? I took a stake in this company as I've been invested in Sareum for many years and felt that Stephen Parker's involvement with MGC would be a good thing. How wrong I was. I hope he now resigns from both MGC and Sareum.

I think you guys are going to be right about 20p a share soon.

Fred, I'm hoping for a Tempest Therapeutics style rise for VAL. They went up 3,973% this month. Details from Bloomberg, below:

"Near-4,000% Surge Catapults One Tiny Biotech Firm to Record Week. Tempest added more than $120 million in market value in October from gain"

https://www.bloomberg.com/news/articles/2023-10-13/near-4-000-surge-catapults-one-tiny-biotech-firm-to-record-week

I have also been reading up on Tempest Therapeutics and, as you pointed out, it went up 3,973% this month, so anything is possible. It would be wonderful to think we will see a similar story with HEMO that appeared in Bloomberg, below:

"Near-4,000% Surge Catapults One Tiny Biotech Firm to Record Week. Tempest added more than $120 million in market value in October from gain" https://www.bloomberg.com/news/articles/2023-10-13/near-4-000-surge-catapults-one-tiny-biotech-firm-to-record-week

Fiercebio is also worth digesting as is the RNS from Tempest, both of which I have pasted here at the foot of my post. This really could be HEMO soon imo and we could be in for a superb share price rise before the end of 2023.

https://www.fiercebiotech.com/biotech/tempests-triplet-treatment-had-advantage-over-roche-combo-liver-cancer

https://ir.tempesttx.com/news-releases/news-release-details/tempest-releases-new-data-demonstrating-superiority-tpst-1120

Thanks for the reply. Prevail has an impressive track record. Hence my investment in Hemo.

I'm a newish investor in HEMO. Does anyone have a realistic feel for what our share price will be when we move into PI clinical trials of HEMO CAR-T? Currently it does not appear to be priced in at all? Once we move in to the clinic that is surely a game changer for the company and 2p will be a distant memory. It also puts HEMO in the licencing shop window. I have seen 15p-20p mentioned on here, which appears to be quite low for a company that's moved in to the clinic or is that about right? Thank you.

SRA737 licensing news could, as you say, come at anytime and see the share price rise significantly. As for the current drop that’s due to Tim Mitchell and Stephen Parker’s decision to buy in to RF rather than raising at 250p+ when we could and should have tapped the markets and HNWI’s for millions. Without a doubt a huge error imo that is costing PI’s every day this nightmare decision to finance the company in this way continues.

It's a confidence issue. I've been a shareholder in Sareum for 13+ years and will remain invested until a takeover happens. However, I didn't feel very positive after the last Investor Meet. The disdain shown to shareholder questions as if we were naughty school children and almost an inconvenience did not resonate well with me. I don't like what has happened over at MGC either where small share holders have been royally shafted and left with nearly nothing. A HNWI is going to be much more cautious about an approach from SP I would suggest given that both MGC and SAR's share prices have been impacted by poor decisions. We should have raised millions when we were at £2.50+. The "experts" do not appear to have PI's best interests at heart. I mentioned recently the chumocracy of the last AGM and I believe Stephen Parker is skating on very thin ice with many long term PIs. I wouldn't be surprised if he resigned soon rather than face shareholders this time. His finest hour was bringing on board the HNWI's but since then it's been a depressing downward spiral for our share price. SP and TM are responsible, in part, for this in my opinion as they are not inspiring or exuding confidence. I believe in SRA737, SDC1801 and 1802 but our board are in danger of being too late to the party.

SAR appear in the "Cambridge Trumpet" every year with the same kind of positive messaging. The trouble is these messages are not PR'd to national or trade publications and journalists. Until they raise their aspirations and target publications that actually are read by decision makers it's not going to have any impact. Good PR is not just RNS announcements it is the drip drip drip of regular comments and features on a daily/weekly basis about Sareum, its key staff and opinions in trade magazines, national newspapers, tv and online. It's an ongoing programme of creating awareness. Sareum don't do this and they should. Many posters on here have been saying the same thing for donkeys years about this issue. Effective PR is particularly useful to small sized businesses. Imagine if Sareum was in The Times today or on Sky / BBC News or was commented about in The Lancet or were offering their views on a cure for cancer or on autoimmune diseases or a cure for Psoriasis etc to national and international publications? Imagine what that would do for the credibility of Sareum not just infront of the investment community but infront of licencing partners. It will enhance Stephen and Tim's hand in negotiating and help to create hunger for Sareum and its science (Oh and by the way it will help the share price, which most investors would be jolly happy about!). In summary, you either want to put your business in the shop window or you don't. It's as simple as that. Those that do make the most of PR tend to be the winners and those that don't tend to be the laggards. Appearing in the local Pampisford publication does nothing for our business. It's just local PR that his neighbours in the pub will see this weekend, nothing more. The company needs to get real with its PR and "ooze confidence" to national and international editors and journalists and not just in the local free sheet.

Until we get alternative funding from HNWI's or a licencing deal for SRA737 and we can then terminate the River Fort Global deal our share price is going to be held back. Sorry but I'm not a fan of this financial arrangement or the evasive answering of most of the questions asked at the investor meeting this week.

Quite right HBD. We do need the newsflow to kick in. The Chumocracy of the last AGM is going to be a bit trickier for Stephen Parker (in particular) to pull off this year having presided over a share price decline from our highs of 440p to the our 70p lows's. Whilst what has happened to MGC today has no direct relevance to SAR it does introduce, for me anyway, a question of credibility. I'm starting to really look at the wisdom of PH being brought in to attract II's, the share consolidation being in our best interests, the RiverFort Global Capital deal and a few other red flags.

I do hope so as the new finance arrangement recently agreed should be terminated the moment funds are achieved via licencing. Today's RNS from MGC, where Stephen Parker, is Non Exec is really bad news for existing shareholders there. I wont get in to the details but it's not a good read.

This is a great reminder of why we are all invested in Sareum. Thank you. I thought your research about 25 of the licencing deals this year being in the "$10 million to $100 million upfront cash" arena was excellent for SRA737. Better still was your snippet that 4 of the licencing deals in 2023 were "over $100 million in upfront cash". That made my day! I hope SRA737 is one of the latter.

As I said only yesterday morning LTH’s understand the Sareum model and history of how this share price fluctuates just prior to news. Lo and behold we get an upbeat RNS today on dosing of SDC1801. £4 a share is nailed on in due course, as you say, and if we achieve a billion licencing or takeover deal then that is x15 of our current share price! That's why we are all here as we can see the bigger picture. I think it's worth repeating it for those that need to hear It again. A £1 Billion deal is x15 of our current share price. Enough said.

Bobbler nailed it during 2020 and 2021 with his predictions of 9p a share. He was posting from sub 1p about the likely timescale of hitting 2p, 4p, 8p etc and do you know what? His predictions were 100% right so who would you rather believe? Bobbler who has done his research and been here for years or some new kid in the block with no research and zero understanding of Sareum. I’ll stick with Bobbler thanks and the other LTH’s that understand the Sareum model and history of how this share price fluctuates just prior to news. SRA737 and 1801 updates are due. If they are good then £3-4 a share is nailed on.

It would certainly help if Sareum Tweeted a link to this data or issued one of their low key "Sareum notes" RNS' about this research.

Meaningful news can come anytime soon. SRA737, Australia update etc. Those of us that have been here a long time and have done our research on Sareum know it's a long term hold for potentially huge rewards.

Aber, I am with you 100%. I believe 100% in the science but I also believe 100% that when we accomplished 455p+ (9-10p old money) we could and should have raised millions when the momentum was with us after our July 1st UKRI RNS, titled: "Completed Covid-19 Research Project Delivers Encouraging Results". The subsequent consolidation was the opportune moment to raise £10million+ at 250p-300p, which would have still been a big discount to the then current price, which was significantly over 300p at the time. We would have been in a really strong financial position to take SDC1801/1802 forward. What are all these finance experts - led by Stephen Parker - doing? If little old me realised a fund raise at 250p-300p was much more in our interests why didn't the real experts do this? We, along with many others here, said at the time that we hoped the consolidation sideshow will be worth it. Why didn't SAR raise millions at 300p when they could have? Why is radio silence the order of the day again? Where is the promised IR expertise and comms? The result is a declining share price. I still expect this to be 150p-200p on positive SRA737 licencing news and over 300p+ on positive SDC 1801/1802 news but the experts need to start delivering with their much heralded expertise. Mini rant over!